Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HY 004 - Juventas Cell Therapy

Next Previous
Search
Drug Profile

HY 004 - Juventas Cell Therapy

Alternative Names: Anti-CD19-anti-CD22 CAR-T cell therapy - Juventas Cell Therapy; HY004 - Juventas Cell Therapy

Latest Information Update: 28 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Juventas Cell Therapy
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 28 Aug 2023 HY 004 is still in preclinical development for Precursor cell lymphoblastic leukaemia-lymphoma in China (IV, Infusion) (NCT06005649) (Juventas Cell Therapy Pipeline, August 2023)
  • 24 Aug 2023 Juventas Cell Therapy plans a phase I/II trial for Precursor cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater ) in August 2023 (IV, Infusion) (NCT06009107)
  • 23 Aug 2023 Juventas Cell Therapy plans a phase I/II trial for Non-hodgkin Lymphoma (Second-line therapy or greater) (IV, Infusion) (NCT06005649)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top